Antigen-specific therapeutic approaches in type 1 diabetes

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 2, 2012, Pages

  Clemente Casares, Xavier ^a,b   Tsai, Sue ^a,b   Huang, Carol ^a   Santamaria, Pere ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERED PEPTIDE LIGAND; ALUMINUM POTASSIUM SULFATE; CHAPERONIN 60; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL TARGETED PEPTIDE; DENDRITIC CELL VACCINE; DIMER; DNA VACCINE; ETHYLENE CARBODIIMIDE; ETHYLENE DERIVATIVE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INSULIN; INTERLEUKIN 10; INTERLEUKIN 4; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NANOPARTICLE; RECOMBINANT ENZYME; RECOMBINANT GLUTAMATE DECARBOXYLASE; SILVER; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTIGEN; ENZYME INHIBITOR;

ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; DENDRITIC CELL; DIABETIC KETOACIDOSIS; DISEASE COURSE; DNA IMMUNIZATION; FOLLOW UP; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; SPLEEN CELL; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG ANTAGONISM; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; REVIEW;

ANIMALS; ANTIGENS; CHAPERONIN 60; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUG EVALUATION; ENZYME INHIBITORS; GLUTAMATE DECARBOXYLASE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INSULIN; VACCINES, DNA;

EID: 84873135697     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a007773     Document Type: Article

References (194)

1. Abastado JP, Lone YC, Casrouge A, Boulot G, Kourilsky P. 1995. Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness. J Exp Med 182: 439-447.
2. Ablamunits V, Elias D, Reshef T, Cohen IR. 1998. Islet T cells secreting IFN-γ in NOD mouse diabetes: Arrest by p277 peptide treatment. J Autoimmun 11: 73-81.
3. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. 1999. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 12: 121-129.
4. Abulafia-Lapid R, Gillis D, Yosef O, Atlan H, Cohen IR. 2003. T cells and autoantibodies to human HSP70 in type 1 diabetes in children. J Autoimmun 20: 313-321.
5. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A. 2005. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19: 238-246.
6. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, et al. 2002. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 51: 2126-2134.
7. Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, et al. 2006. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol 63: 59-69.
8. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. 2000. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 406: 739-742.
9. Anderton SM, Manickasingham SP, Burkhart C, Luckcuck TA, Holland SJ, Lamont AG, Wraith DC. 1998. Fine specificity of the myelin-reactive T cell repertoire: Implications for TCR antagonism in autoimmunity. J Immunol 161: 3357-3364.
10. Aspord C, Thivolet C. 2002. Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 130: 204-211.
11. Atkinson MA, Maclaren NK, Luchetta R. 1990. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39: 933-937.
12. Atkinson MA, Kaufman DL, Newman D, Tobin AJ, Maclaren NK. 1993. Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest 91: 350-356.
13. Axelsson S, Hjorth M, Akerman L, Ludvigsson J, Casas R. 2010. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65). Diabetes Metab Res Rev 26: 559-568.
14. Baekkeskov S, Landin M, Kristensen JK, Srikanta S, Bruining GJ, Mandrup-Poulsen T, de Beaufort C, Soeldner JS, Eisenbarth G, Lindgren F, et al. 1987. Antibodies to a 64, 000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. J Clin Invest 79: 926-934.
15. Baekkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, Lernmark A. 1982. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 298: 167-169.
16. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, Lindblad M, MayerA, Czerkinsky C, Holmgren J, et al. 1997. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci 94: 4610-4614.
17. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, EatonJ, Antel J, Frank JA, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 6: 1167-1175.
18. Birk OS, Elias D, Weiss AS, Rosen A, van-der Zee R, Walker MD, Cohen IR. 1996. NOD mouse diabetes: The ubiquitous mouse hsp60 is a β-cell target antigen of autoimmune T cells. J Autoimmun 9: 159-166.
19. + T cell tolerance. J Exp Med 196: 1627-1638.
20. Bot A, Smith D, Bot S, Hughes A, Wolfe T, Wang L, Woods C, von Herrath M. 2001. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 167: 2950-2955.
21. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von HerrathM. 2006. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116: 1371-1381.
22. Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M. 2010. Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 18: 307-316.
23. Bridgett M, Cetkovic-Cvrlje M, O'Rourke R, Shi Y, Narayanswami S, Lambert J, Ramiya V, Baekkeskov S, Leiter EH. 1998. Differential protection in two transgenic lines of NOD/Lt mice hyperexpressing the autoantigen GAD65 in pancreatic β-cells. Diabetes 47: 1848-1856.
24. Bruder D, Westendorf AM, Hansen W, Prettin S, Gruber AD, Qian Y, von Boehmer H, Mahnke K, Buer J. 2005. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 54: 3395-3401.
25. Brumeanu TD, Swiggard WJ, Steinman RM, Bona CA, Zaghouani H. 1993. Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus. J Exp Med 178: 1795-1799.
26. Bu DF, Erlander MG, Hitz BC, Tillakaratne NJ, Kaufman DL, Wagner-McPhersonCB, Evans GA, Tobin AJ. 1992. Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci 89: 2115-2119.
27. Carter JE 3rd., Yu J, Choi NW, Hough J, Henderson D, He D, Langridge WH. 2006. Bacterial and plant enterotoxin B subunit-autoantigen fusion proteins suppress diabetes insulitis. Mol Biotechnol 32: 1-15.
28. + T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 3: 383-391.
29. Cetkovic-Cvrlje M, Gerling IC, Muir A, Atkinson MA, Elliott JF, Leiter EH. 1997. Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate β-cell antigens. Diabetes 46: 1975-1982.
30. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, et al. 2000. Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356: 545-549.
31. Chang Y, Yap S, Ge X, Piganelli J, Bertera S, Giannokakis N, Mathews C, Prud'homme G, Trucco M. 2005. DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice. Gene Ther 12: 1679-1685.
32. Chen W, Bergerot I, Elliott JF, Harrison LC, Abiru N, Eisenbarth GS, DelovitchTL. 2001. Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol 167: 4926-4935.
33. Chen D, Maa YF, Haynes JR. 2002. Needle-free epidermal powder immunization. Expert Rev Vaccines 1: 265-276.
34. Chen C, Lee WH, Yun P, Snow P, Liu CP. 2003. Induction of autoantigen-specific Th2 and Tr1 regulatory T cells and modulation of autoimmune diabetes. J Immunol 171: 733-744.
35. Cheramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R. 2010. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response. Clin Immunol 137: 31-40.
36. Christgau S, Schierbeck H, Aanstoot HJ, Aagaard L, Begley K, Kofod H, HejnaesK, Baekkeskov S. 1991. Pancreatic β cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble. J Biol Chem 266: 23516.
37. Christie MR, Tun RY, Lo SS, Cassidy D, Brown TJ, Hollands J, Shattock M, Bottazzo GF, Leslie RD. 1992. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins. Diabetes 41: 782-787.
38. Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C. 1992. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 90: 741-748.
39. Clemente-Casares X, Tsai S, Yang Y, Santamaria P. 2011. Peptide-MHC-based nanovaccines for the treatment of autoimmunity: A "one size fits all" approach? J Mol Med 89: 733-742.
40. Coon B, An LL, Whitton JL, von Herrath MG. 1999. DNA immunization to prevent autoimmune diabetes. J Clin Invest 104: 189-194.
41. Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, Thielemans K, Gambhir SS, Fathman CG. 2008. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol 127: 176-187.
42. Daniel D, Wegmann DR. 1996a. Intranasal administration of insulin peptide B: 9-23 protects NOD mice from diabetes. Ann NY Acad Sci 778: 371-372.
43. Daniel D, Wegmann DR. 1996b. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci 93: 956-960.
44. Danko I, Fritz JD, Jiao S, Hogan K, Latendresse JS, Wolff JA. 1994. Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Ther 1: 114-121.
45. De Aizpurua HJ, Wilson YM, Harrison LC. 1992. Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes. Proc Natl Acad Sci 89: 9841-9845.
46. Devendra D, Paronen J, Moriyama H, Miao D, Eisenbarth GS, Liu E. 2004. Differential immune response to B: 9-23 insulin 1 and insulin 2 peptides in animal models of type 1 diabetes. J Autoimmun 23: 17-26.
47. Diabetes Prevention Trial-Type 1 Diabetes Study Group. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346: 1685-1691.
48. Elias D, Cohen IR. 1994. Peptide therapy for diabetes in NOD mice. Lancet 343: 704-706.
49. Elias D, Cohen IR. 1995. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide 277. Diabetes 44: 1132-1138.
50. Elias D, Markovits D, Reshef T, van der Zee R, Cohen IR. 1990. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci 87: 1576-1580.
51. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR. 1991. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci 88: 3088-3091.
52. Elias D, Marcus H, Reshef T, Ablamunits V, Cohen IR. 1995. Induction of diabetes in standard mice by immunization with the p277 peptide of a 60-kDa heat shock protein. Eur J Immunol 25: 2851-2857.
53. Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Konen-Waisman S, Cohen IR. 1997. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various β-cell antigens. Diabetes 46: 758-764.
54. Elliott JF, Qin HY, Bhatti S, Smith DK, Singh RK, Dillon T, Lauzon J, Singh B. 1994. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice. Diabetes 43: 1494-1499.
55. Endl J, Otto H, Jung G, Dreisbusch B, Donie F, Stahl P, Elbracht R, Schmitz G, Meinl E, Hummel M, et al. 1997. Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest 99: 2405-2415.
56. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ. 1991. Two genes encode distinct glutamate decarboxylases. Neuron 7: 91-100.
57. Evavold BD, Allen PM. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252: 1308-1310.
58. Evavold BD, Sloan-Lancaster J, Allen PM. 1993. Tickling the TCR: Selective T-cell functions stimulated by altered peptide ligands. Immunol Today 14: 602-609.
59. + T cells that prevent experimental autoimmune diabetes. J Immunol 176: 4608-4615.
60. Faulkner-Jones BE, Cram DS, Kun J, Harrison LC. 1993. Localization and quantitation of expression of two glutamate decarboxylase genes in pancreatic β-cells and other peripheral tissues of mouse and rat. Endocrinology 133: 2962-2972.
61. Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. 1999. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 48: 2300-2308.
62. Feili-Hariri M, Falkner DH, Gambotto A, Papworth GD, Watkins SC, RobbinsPD, Morel PA. 2003. Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum Gene Ther 14: 13-23.
63. Feili-Hariri M, Falkner DH, Morel PA. 2002. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur J Immunol 32: 2021-2030.
64. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. 2006. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 203: 2737-2747.
65. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. 2009. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10: 1185-1192.
66. Filippova M, Liu J, Escher A. 2001. Effects of plasmid DNA injection on cyclophosphamide-accelerated diabetes in NOD mice. DNA Cell Biol 20: 175-181.
67. Fischer B, Elias D, Bretzel RG, Linn T. 2010. Immunomodulation with heat shock protein DiaPep277 to preserve β cell function in type 1 diabetes-an update. Expert Opin Biol Ther 10: 265-272.
68. Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J, Colman PG, Harrison LC. 2011. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60: 1237-1245.
69. Fousteri G, Dave A, Bot A, Juntti T, Omid S, von Herrath M. 2010. Subcutaneous insulin B: 9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNγ. Diabetologia 53: 1958-1970.
70. Frelin L, Brass A, Ahlen G, Brenndorfer ED, Chen M, Sallberg M. 2010. Electroporation: A promising method for the nonviral delivery of DNA vaccines in humans? Drug News Perspect 23: 647-653.
71. Gauvrit A, Debailleul M, Vu AT, Sai P, Bach JM. 2004. DNA vaccination encoding glutamic acid decarboxylase can enhance insulitis and diabetes in correlation with a specific Th2/3 CD4 T cell response in non-obese diabetic mice. Clin Exp Immunol 137: 253-262.
72. Geluk A, van Meijgaarden KE, Roep BO, Ottenhoff TH. 1998. Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes. J Autoimmun 11: 353-361.
73. Geng L, Solimena M, Flavell RA, Sherwin RS, Hayday AC. 1998. Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease. Proc Natl Acad Sci 95: 10055-10060.
74. Glinka Y, Chang Y, Prud'homme GJ. 2006. Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand. Mol Ther 14: 578-587.
75. Gottlieb P, Eisenbarth G, Kipnes M, Ratner R, Rockell J, Wagner R, Solvason N, Tersini K, Valone F, Woody K, et al. 2008. Interim results of a phase I/II clinical trial of a DNA plasmid vaccine (BHT-3021) for type 1 diabetes. Diabetologia 51 (Abstr): 574.
76. Goudy KS, Wang B, Tisch R. 2008. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin Immunol 129: 49-57.
77. Gregg RK, Jain R, Schoenleber SJ, Divekar R, Bell JJ, Lee HH, Yu P, Zaghouani H. 2004. A sudden decline in active membrane-bound TGF-β impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol 173: 7308-7316.
78. Han B, Serra P, Amrani A, Yamanouchi J, Maree AF, Edelstein-Keshet L, Santamaria P. 2005. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: High efficiency of a low-affinity peptide. Nat Med 11: 645-652.
79. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. 1996. Aerosol insulin induces regulatory CD8 γ δ T cells that prevent murine insulin-dependent diabetes. J Exp Med 184: 2167-2174.
80. Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, Couper JJ, Colman PG. 2004. Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27: 2348-2355.
81. He FR, Zhu HF, Huang H, Dai YD, Shen X, Wang M, Li L, Xing W, Shen GX. 2008. Programmed death-1 ligands-transfected dendritic cells loaded with glutamic acid decarboxylase 65 (GAD65) inhibit both the alloresponse and the GAD65-reactive lymphocyte response. Clin Exp Immunol 151: 86-93.
82. Herrmann SH, Mescher MF. 1986. The requirements for antigen multivalency in class I antigen recognition and triggering of primed precursor cytolytic T lymphocytes. J Immunol 136: 2816-2825.
83. + cells in type 1 diabetic patients. Clin Immunol 138: 117-126.
84. Honeyman MC, Cram DS, Harrison LC. 1993. Glutamic acid decarboxylase 67-reactive T cells: A marker of insulin-dependent diabetes. J Exp Med 177: 535-540.
85. Hutchings PR, Cooke A. 1995. Comparative study of the protective effect afforded by intravenous administration of bovine or ovine insulin to young NOD mice. Diabetes 44: 906-910.
86. Hutchings P, Cooke A. 1998. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration. J Autoimmun 11: 127-130.
87. Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. 2007. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 23: 269-275.
88. Huurman VA, van der Meide PE, Duinkerken G, Willemen S, Cohen IR, Elias D, Roep BO. 2008. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 152: 488-497.
89. Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H. 2003. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J Exp Med 197: 1635-1644.
90. Jain R, Tartar DM, Gregg RK, Divekar RD, Bell JJ, Lee HH, Yu P, Ellis JS, HoemanCM, Franklin CL, et al. 2008. Innocuous IFNγ induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 205: 207-218.
91. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, NussenzweigMC. 1995. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375: 151-155.
92. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6: 1176-1182.
93. Karges W, Pechhold K, Al Dahouk S, Riegger I, Rief M, Wissmann A, Schirmbeck R, Barth C, Boehm BO. 2002. Induction of autoimmune diabetes through insulin (but not GAD65) DNA vaccination in nonobese diabetic and in RIP-B7. 1 mice. Diabetes 51: 3237-3244.
94. Karlsen AE, Hagopian WA, Petersen JS, Boel E, Dyrberg T, Grubin CE, MichelsenBK, Madsen OD, Lernmark A. 1992. Recombinant glutamic acid decarboxylase (representing the single isoform expressed in human islets) detects IDDM-associated 64, 000-M(r) autoantibodies. Diabetes 41: 1355-1359.
95. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV. 1993. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69-72.
96. Kuglin B, Gries FA, Kolb H. 1988. Evidence of IgG autoantibodies against human proinsulin in patients with IDDM before insulin treatment. Diabetes 37: 130-132.
97. + T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol 128: 23-30.
98. Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z. 2007. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: A randomised, double-blind phase II study. Diabetes Metab Res Rev 23: 286-291.
99. + regulatory T cells in vitro. Vaccine 24: 5036-5046.
100. Li L, Yi Z, Wang B, Tisch R. 2009. Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination. J Immunol 183: 4809-4816.
101. Lieberman SM, DiLorenzo TP. 2003. A comprehensive guide to antibody and T-cell responses in type 1 diabetes. Tissue Antigens 62: 359-377.
102. Lin M, Stoica-Nazarov C, Surls J, Kehl M, Bona C, Olsen C, Brumeanu TD, Casares S. 2010. Reversal of type 1 diabetes by a new MHC II-peptide chimera: "Single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process. Eur J Immunol 40: 2277-2288.
103. Liu E, Moriyama H, Abiru N, Miao D, Yu L, Taylor RM, Finkelman FD, EisenbarthGS. 2002. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B: 9-23 and B: 13-23. J Clin Invest 110: 1021-1027.
104. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, et al. 2008. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359: 1909-1920.
105. Ludvigsson J, Hjorth M, Cheramy M, Axelsson S, Pihl M, Forsander G, NilssonNO, Samuelsson BO, Wood T, Aman J, et al. 2011. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: A randomised controlled trial. Diabetologia 54: 634-640.
106. Ma SW, Zhao DL, Yin ZQ, Mukherjee R, Singh B, Qin HY, Stiller CR, Jevnikar AM. 1997. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med 3: 793-796.
107. Ma L, Qian S, Liang X, Wang L, Woodward JE, Giannoukakis N, Robbins PD, Bertera S, Trucco M, Fung JJ, et al. 2003. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-κB activity. Diabetes 52: 1976-1985.
108. Ma S, Huang Y, Yin Z, Menassa R, Brandle JE, Jevnikar AM. 2004. Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc Natl Acad Sci 101: 5680-5685.
109. Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. 2004. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 173: 4331-4341.
110. +regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101: 4862-4869.
111. Marin-Gallen S, Clemente-Casares X, Planas R, Pujol-Autonell I, Carrascal J, Carrillo J, Ampudia R, Verdaguer J, Pujol-Borrell R, Borras FE, et al. 2010. Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol 160: 207-214.
112. Maron R, Melican NS, Weiner HL. 1999. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally-and nasally-treated NOD mice suppress diabetes. J Autoimmun 12: 251-258.
113. Martinez NR, Augstein P, Moustakas AK, Papadopoulos GK, Gregori S, AdoriniL, Jackson DC, Harrison LC. 2003. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 111: 1365-1371.
114. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA. 2003. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol 171: 5587-5595.
115. McCluskey J, Blok R, Kjer-Nielsen L. 1989. The role of major histocompatibility molecules in antigen-specific immune responses. Transplant Proc 21: 591-594.
116. Merani S, Shapiro AM. 2006. Current status of pancreatic islet transplantation. Clin Sci (Lond) 110: 611-625.
117. Monti P, Scirpoli M, Maffi P, Ghidoli N, De Taddeo F, Bertuzzi F, Piemonti L, Falcone M, Secchi A, Bonifacio E. 2008. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 118: 1806-1814.
118. Morel PA, Vasquez AC, Feili-Hariri M. 1999. Immunobiology of DC in NOD mice. J Leukoc Biol 66: 276-280.
119. Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta R, Krischer J, Maclaren N. 1995. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-γ transcription. J Clin Invest 95: 628-634.
120. + T cells in NOD mice. Proc Natl Acad Sci 105: 6374-6379.
121. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, WegmannDR, Hutton JC, Elliott JF, et al. 2005. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435: 220-223.
122. Nanto-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipila JI, Haavisto L, et al. 2008. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. Lancet 372: 1746-1755.
123. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S. 2003. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348: 2294-2303.
124. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, RaskinP, Zinman B. 2005. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653.
125. Niens M, Grier AE, Marron M, Kay TW, Greiner DL, Serreze DV. 2011. Prevention of "humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach. Diabetes 60: 1229-1236.
126. Nussbaum G, Zanin-Zhorov A, Quintana F, Lider O, Cohen IR. 2006. Peptide p277 of HSP60 signals T cells: Inhibition of inflammatory chemotaxis. Int Immunol 18: 1413-1419.
127. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, et al. 2010. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 34: 408-415.
128. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL. 1983. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222: 1337-1339.
129. Panina-Bordignon P, Lang R, van Endert PM, Benazzi E, Felix AM, Pastore RM, Spinas GA, Sinigaglia F. 1995. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 181: 1923-1927.
130. Perone MJ, Bertera S, Tawadrous ZS, Shufesky WJ, Piganelli JD, Baum LG, TruccoM, Morelli AE. 2006. Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. J Immunol 177: 5278-5289.
131. + T cells into regulatory T cells and promotes immunotolerance in NOD mice. Rev Diabet Stud 7: 47-61.
132. Pleau JM, Fernandez-Saravia F, Esling A, Homo-Delarche F, Dardenne M. 1995. Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). Clin Immunol Immunopathol 76: 90-95.
133. Plesner A, Worsaae A, Dyrberg T, Gotfredsen C, Michelsen BK, Petersen JS. 1998. Immunization of diabetes-prone or non-diabetes-prone mice with GAD65 does not induce diabetes or islet cell pathology. J Autoimmun 11: 335-341.
134. + T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 56: 1395-1402.
135. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, Spera S, SuraciC, Multari G, Cervoni M, et al. 2000. No effect of oral insulin on residual β-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 43: 1000-1004.
136. Preda I, McEvoy RC, Lin M, Bona CA, Rapaport R, Brumeanu TD, Casares S. 2005. Soluble, dimeric HLA DR4-peptide chimeras: An approach for detection and immunoregulation of human type-1 diabetes. Eur J Immunol 35: 2762-2775.
137. Prud'homme GJ, Chang Y, Li X. 2002. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Hum Gene Ther 13: 395-406.
138. Prud'homme GJ, Draghia-Akli R, Wang Q. 2007. Plasmid-based gene therapy of diabetes mellitus. Gene Ther 14: 553-564.
139. Quintana FJ, Rotem A, Carmi P, Cohen IR. 2000. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: Modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 165: 6148-6155.
140. Ramiya VK, Shang XZ, Wasserfall CH, Maclaren NK. 1997. Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice. Autoimmunity 26: 139-151.
141. Ravanan R, Wong SF, Morgan NG, Mathieson PW, Smith RM. 2007. Inhalation of glutamic acid decarboxylase 65-derived peptides can protect against recurrent autoimmune but not alloimmune responses in the non-obese diabetic mouse. Clin Exp Immunol 148: 368-372.
142. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. 2001. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 358: 1749-1753.
143. Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D. 2007. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: Extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 23: 292-298.
144. Rivas EI, Driver JP, Garabatos N, Presa M, Mora C, Rodriguez F, Serreze DV, Stratmann T. 2011. Targeting of a T cell agonist peptide to lysosomes by DNA vaccination induces tolerance in the nonobese diabetic mouse. J Immunol 186: 4078-4087.
145. Robertson RP. 2010. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 59: 1285-1291.
146. Rudy G, Stone N, Harrison LC, Colman PG, McNair P, Brusic V, French MB, Honeyman MC, Tait B, Lew AM. 1995. Similar peptides from two β cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol Med 1: 625-633.
147. Ruffner MA, Robbins PD. 2010. Dendritic cells transduced to express interleukin 4 reduce diabetes onset in both normoglycemic and prediabetic nonobese diabetic mice. PLoS One 5: e11848.
148. Sai P, Damage C, Rivereau AS, Hoeltzel A, Gouin E. 1996. Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice. J Autoimmun 9: 713-722.
149. Schloot NC, Meierhoff G, Lengyel C, Vandorfi G, Takacs J, Panczel P, Barkai L, Madacsy L, Oroszlan T, Kovacs P, et al. 2007. Effect of heat shock protein peptide DiaPep277 on β-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: Two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 23: 276-285.
150. Seissler J, Amann J, Mauch L, Haubruck H, Wolfahrt S, Bieg S, Richter W, Holl R, Heinze E, Northemann W, et al. 1993. Prevalence of autoantibodies to the 65-and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 92: 1394-1399.
151. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230-238.
152. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, et al. 2006. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355: 1318-1330.
153. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. 2005. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28: 1068-1076.
154. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L. 2008. Type 1 Diabetes TrialNet-an international collaborative clinical trials network. Ann NY Acad Sci 1150: 14-24.
155. Sloan-Lancaster J, Allen PM. 1996. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology. Annu Rev Immunol 14: 1-27.
156. Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, Ocampo A, YunR, Ahmad S, Liu E, et al. 2008. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol 181: 8298-8307.
157. Speight J, Reaney MD, Woodcock AJ, Smith RM, Shaw JA. 2010. Patient-reported outcomes following islet cell or pancreas transplantation (alone or after kidney) in Type 1 diabetes: A systematic review. Diabet Med 27: 812-822.
158. Steffes MW, Sibley S, Jackson M, Thomas W. 2003. β-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26: 832-836.
159. Steinman RM, Hawiger D, Nussenzweig MC. 2003. Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711.
160. Tai N, Yasuda H, Xiang Y, Zhang L, Rodriguez-Pinto D, Yokono K, Sherwin R, Wong FS, Nagata M, Wen L. 2011. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7. 1 mice. Clin Immunol 139: 336-349.
161. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. 2004. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199: 1455-1465.
162. + T helper intermediates display suppressive function against autoimmune diabetes. J Immunol 184: 3377-3385.
163. The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986.
164. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389.
165. Thivolet CH, Tappaz M, Durand A, Petersen J, Stefanutti A, Chatelain P, Vialettes B, Scherbaum W, Orgiazzi J. 1992. Glutamic acid decarboxylase (GAD) autoantibodies are additional predictive markers of type 1 (insulin-dependent) diabetes mellitus in high risk individuals. Diabetologia 35: 570-576.
166. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, LehmannPV, Kaufman DL. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183: 1561-1567.
167. Tian J, Dang H, von Boehmer H, Jaeckel E, Kaufman DL. 2009. Transgenically induced GAD tolerance curtails the development of early β-cell autoreactivities but causes the subsequent development of supernormal autoreactivities to other β-cell antigens. Diabetes 58: 2843-2850.
168. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. 1993. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366: 72-75.
169. Tisch R, Wang B, Serreze DV. 1999. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 163: 1178-1187.
170. Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, Serreze DV. 2001. Antigen-specific mediated suppression of β cell autoimmunity by plasmid DNA vaccination. J Immunol 166: 2122-2132.
171. + effector/memory T cells from type 1 diabetic individuals. J Clin Immunol 30: 659-668.
172. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, Yang Y, Medarova Z, Moore A, Santamaria P. 2010. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32: 568-580.
173. Tuomilehto J, Zimmet P, Mackay IR, Koskela P, Vidgren G, Toivanen L, Tuomilehto-Wolf E, Kohtamaki K, Stengard J, Rowley MJ. 1994. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet 343: 1383-1385.
174. Turley DM, Miller SD. 2007. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol 178: 2212-2220.
175. Uibo R, Lernmark A. 2008. GAD65 autoimmunity-clinical studies. Adv Immunol 100: 39-78.
176. Urbanek-Ruiz I, Ruiz PJ, Paragas V, Garren H, Steinman L, Fathman CG. 2001. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clin Immunol 100: 164-171.
177. Velthuis JH, Unger WW, van der Slik AR, Duinkerken G, Engelse M, Schaapherder AF, Ringers J, van Kooten C, de Koning EJ, Roep BO. 2009. Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia 52: 494-503.
178. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS. 1996. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45: 926-933.
179. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R. 2009. No effect of the altered peptide ligand NBI-6024 on β-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32: 2036-2040.
180. Wegmann DR, Gill RG, Norbury-Glaser M, Schloot N, Daniel D. 1994a. Analysis of the spontaneous T cell response to insulin in NOD mice. J Autoimmun 7: 833-843.
181. Wegmann DR, Norbury-Glaser M, Daniel D. 1994b. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 24: 1853-1857.
182. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, GottliebPA, Greenbaum CJ, Herold KC, Marks JB, et al. 2011. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. Lancet 378: 319-327.
183. Wiest-Ladenburger U, Fortnagel A, Richter W, Reimann J, Boehm BO. 1998. DNA vaccination with glutamic acid decarboxylase (GAD) generates a strong humoral immune response in BALB/c, C57BL/6, and in diabetes-prone NOD mice. Horm Metab Res 30: 605-609.
184. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. 1990. Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
185. Xia CQ, Peng R, Qiu Y, Annamalai M, Gordon D, Clare-Salzler MJ. 2007. Transfusion of apoptotic β-cells induces immune tolerance to β-cell antigens and prevents type 1 diabetes in NOD mice. Diabetes 56: 2116-2123.
186. Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, Hirasawa K, SherwinRS, Jun HS. 1999. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in β cells. Science 284: 1183-1187.
187. You S, Chen C, Lee WH, Brusko T, Atkinson M, Liu CP. 2004. Presence of diabetes-inhibiting, glutamic acid decarboxylase-specific, IL-10-dependent, regulatory T cells in naive nonobese diabetic mice. J Immunol 173: 6777-6785.
188. Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS. 2000. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci 97: 1701-1706.
189. Zaghouani H, Steinman R, Nonacs R, Shah H, Gerhard W, Bona C. 1993. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science 259: 224-227.
190. Zanin-Zhorov A, Tal G, Shivtiel S, Cohen M, Lapidot T, Nussbaum G, MargalitR, Cohen IR, Lider O. 2005. Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells: Effects on signaling, chemotaxis, and inflammation. J Immunol 175: 276-285.
191. + regulatory T cell function via innate TLR2 signaling. J Clin Invest 116: 2022-2032.
192. + Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 101: 68-73.
193. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. 1991. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci 88: 10252-10256.
194. Zhang L, Nakayama M, Eisenbarth GS. 2008. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 20: 111-118.